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The carnitine/organic cation transporter (OCTN) family consists of three transporter isoforms, i.e., 
OCTN1 (SLC22A4) and OCTN2 (SLC22A5) in humans and animals and Octn3 (Slc22a21) in mice.  
These transporters are physiologically essential to maintain appropriate systemic and tissue 
concentrations of carnitine by regulating its membrane transport during intestinal absorption, tissue 
distribution, and renal reabsorption.  Among them, OCTN2 is a sodium-dependent, high-affinity 
transporter of carnitine, and functional defect of OCTN2 due to genetic mutation causes primary 
systemic carnitine deficiency (SCD).  Since carnitine is essential for beta-oxidation of long-chain 
fatty acids to produce ATP, OCTN2 gene mutation causes a range of symptoms, including 
cardiomyopathy, skeletal muscle weakness, fatty liver, and male infertility.  These functional 
consequences of Octn2 gene mutation can be clearly seen in an animal model, jvs mouse, which 
exhibits the SCD phenotype.  In addition, although the mechanism is not clear, single nucleotide 
polymorphisms of OCTN1 and OCTN2 genes are associated with increased incidences of 
rheumatoid arthritis, Crohn’s disease and asthma.  OCTN1 and OCTN2 accept cationic drugs as 
substrates and contribute to intestinal and pulmonary absorption, tissue distribution (including to 
tumor cells), and renal excretion of these drugs.  Modulation of the transport activity of OCTN2 by 
externally administered drugs may cause drug-induced secondary carnitine deficiency.  Octn3 
transports carnitine specifically, particularly in male reproductive tissues.  Thus, the OCTNs are 
physiologically, pathologically and pharmacologically important.  Detailed characterization of 
these transporters will greatly improve our understanding of the pathology associated with common 
diseases caused by functional deficiency of OCTNs.        
 







The carnitine/organic cation transporters OCTNs are classified as organic ion transporters in 
subfamily of 22A of the solute carrier (SLC) transporter superfamily, which includes organic cation 
transporters (OCTs), organic anion transporters (OATs) and carnitine/organic cation transporters 
(OCTNs).  OCTs and OATs are categorized as transporters for cationic and anionic molecules 
(including xenobiotics), respectively; they can significantly affect drug disposition, and accordingly, 
they have to be considered as potential sites of drug-drug interaction during the clinical development 
of new drugs [1].  OCTNs are unique in recognizing zwitter-ionic carnitine 
(beta-hydroxy-gamma-trimethylaminobutyric acid) as an endogenous substrate, and they also 
recognize various xenobiotics, mainly cationic compounds.  In mice, three isoforms, Octn1 
(Slc22a4), Octn2 (Slc22a5) and Octn3 (Slc22a21), have been identified, while in humans there are 
two isoforms, OCTN1 (SLC22A4) and OCTN2 (SLC22A5) [2,3,4].   
In humans, OCTN1 was discovered in 1997, and then OCTN2, the sodium ion-dependent carnitine 
transporter, was found in 1998 [2,3].  Systemic carnitine deficiency (SCD) arising from deficiency 
of OCTN2 was found as an inherited disease OMIM212149 in 1999 [5].  Immediately thereafter, 
cDNA cloning of human OCTNs and murine Octn1, 2 and 3 was achieved and the transporter 
molecules were functionally characterized [4] (Table 1).  Here, the functional characteristics and 
roles of OCTNs in tissues will be comprehensively reviewed, focusing especially on OCTN2, which 
has been better characterized, partly because of its well-established physiological role as a sodium 
ion-dependent high-affinity carnitine transporter.  The relationship of these transporters with 
various diseases is also considered, and their pharmacological and toxicological relevance is 
discussed 
 
1: Characteristics of OCTN1 
Initially, OCTN1 was found as a gene specifically expressed in fetal but not adult liver, and having 
only 30% similarity in primary amino acid sequence to other organic cation transporters (OCTs) with 
11 to 12 putative membrane-spanning domains [2].  Accordingly, it was thought to be a novel 
transporter showing similar characteristics to OCTs.  But, uniquely, it has a nucleotide-binding site 
motif, although ATP dependence of OCTNs has not been reported.  Therefore, it appeared to be a 
Novel organic cation transporter from a functional viewpoint, because of the Nucleotide-binding site 
motif [2]; this is the reason why this transporter is named OCTN.  When OCTN1 is expressed in 
HEK293 cells, it exhibits transport activity for the organic cation tetraethylammonium (TEA). 
OCTN1-mediated TEA transport is pH dependent, with a lower activity at acidic pH, suggesting that 
OCTN1 may be an organic cation/proton exchange transporter.  In addition, OCTN1 is localized at 
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the apical membrane of renal tubular epithelial cells [6].  Accordingly, considering that the tubular 
luminal pH is more acidic than the intracellular pH, it is conceivable that OCTN1 functions as an 
organic cation/proton exchanger in kidney, mediating the excretion of cationic compounds into urine.  
Such a transporter had long been suspected to be present on the basis of membrane physiological 
studies [2,6].  Although the physiological role of OCTN1 is not well established, it preferentially 
transports the anti-oxidant ergothioneine in a sodium ion-dependent manner. Accordingly, it has been 
suggested that the physiological role of OCTN1 is intracellular accumulation of ergothioneine for 
relief of oxidative stress [7,8].  In addition, OCTN1 was suggested to be involved in the 
development of inflammatory or autoimmune diseases such as rheumatoid arthritis and Crohn’s 
disease [9,10,11].  Octn1 gene (Slc22a4) knockout mice are associated with the phenotype of 
intestinal tissue damage, suggesting that OCTN1 has an essential physiological role in the intestines, 
and a functional defect is associated with disease [12].  These ideas are consistent with the fact that 
Octn1-knockout mice exhibit a significant change in disposition of ergothioneine, based on 
metabolome analysis [12].  As described above, OCTN1 may also contribute to drug transport in 
the kidney, because it accepts drugs such as quinidine, pyrilamine, verapamil and oxaliplatin as 
substrates, as well as TEA [13,14] (Table 1).  It is also reported that renal clearance of the 
anticonvulsant gabapentin is decreased in individuals with single nucleotide polymorphism (SNP) 
leading to non-synonymous mutation of leucine at codon 503 to phenylalanine [15].  This mutation 
causes a decrease in OCTN1-mediated transport of gabapentin, as verified in vitro, suggesting the in 
vivo pharmacokinetic relevance of OCTN1 as a contributor to renal secretion of this drug.  
Although there is some experimental evidence that OCTN1 has other pharmacological and 
pathophysiological roles, most of these findings require confirmation, and the extent of OCTN1’s 
contribution also remains to be clarified. 
 
2: Sodium-dependent, high-affinity carnitine transporter, OCTN2 
OCTN2 is responsible for transport of carnitine, which is partially biosynthesized from lysine and 
methionine and is essential for beta-oxidation of long-chain fatty acids in mitochondria.  Without 
carnitine, fatty acids are unable to cross the inner membrane of a mitochondria, where beta-oxidation 
reaction occurs, since fatty acids are translocated as acylcarnitine esters (formed by carnitine 
palmitoyl transferase 1, CPT1) into mitochondria via carnitine acylcarnitine translocase (CACT) 
[16].  Skeletal muscle and cardiac muscle utilize fatty acids as an energy source; therefore, a 
deficiency of carnitine in these tissues leads to cardiomyopathy and muscle weakness. In juvenile 
visceral steatosis (jvs) mice, which exhibit a SCD phenotype, alterations in intestinal absorption, 
tissue distribution and elimination of carnitine have been observed [17,18].  Pathologically, jvs 
mice display severe lipid accumulation in the liver, hypoglycemia, hyperammonemia, and growth 
retardation [17]. Table 2 shows PK parameters after administration of [3H]carnitine in normal and jvs 
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mice, based on our previous studies. Comparison of the PK parameters reveals that total clearance is 
increased in jvs mice, while volume of distribution, tissue-to-plasma concentration ratio and 
bioavailability after oral administration are significantly decreased [18].  Such alterations in PK 
parameters of carnitine in jvs mice can be explained by decreased membrane permeability in 
intestinal and other tissues and reduced reabsorption in kidney, leading us to hypothesize that 
membrane transporter function for carnitine is impaired in these tissues. Further in vitro study has 
demonstrated decreased membrane permeability in primary-cultured fibroblast cells prepared from 
jvs mice [19].  Finally, it was confirmed that OCTN2/Octn2 is a molecular determinant of 
membrane permeability of carnitine, and the transporter was characterized as a high-affinity, sodium 
ion-dependent transporter of carnitine [3]. We confirmed that carnitine transport activity is impaired 
due to mutation of the Octn2 gene in jvs mice and mutation of the OCTN2 gene in SCD patients [5].  
The Octn2 gene in jvs mice exhibits a single nonsynonymous mutation in codon 352 that results in a 
change of the amino acid residue from leucine to arginine, and this mutation resulted in loss of 
carnitine transport activity when expressed in vitro in cultured cells [5].  In addition, Japanese 
individuals and familial members who are affected by carnitine deficiency have been reported to 
have various mutations in the OCTN2 gene, all of which are associated with loss or decrease of 
carnitine transport activity [5].  OCTN2 is now generally accepted to be the causal gene of the 
genetic disease SCD (OMIM212149). 
 
Based on membrane physiological studies, it has been suggested that several types of carnitine 
transporters are expressed in various cells and tissues, including high- and low-affinity types and 
sodium ion-dependent and -independent types [20] (Table 1). Among them, OCTN2 is classified as a 
high-affinity, sodium ion-dependent carnitine transporter that is essential to maintain appropriate 
systemic and tissue carnitine concentrations, since loss of functional OCTN2 leads to SCD.   
        
3: Role of OCTN2 in carnitine transport in somatic tissues 
OCTN2 is expressed in various tissues. It is abundant in kidney, skeletal muscle, placenta, heart, 
prostate and thyroid, and to lesser extent, in small intestine, liver, lung, brain, trachea, pancreas and 
others [3], suggesting that the expression of OCTN2 is associated with beta-oxidation capacity of 
tissues. The tissue distribution of OCTN1 and OCTN2 mRNA (or protein) expression is summarized 
in Table 1. The putative roles of OCTN2 based on its intracellular protein localization in each tissue 
are summarized in Figure 1. 
3-1: Kidney; In jvs mice, the plasma concentration of carnitine is significantly decreased. Carnitine 
is excreted into urine as a result of glomerular filtration, because it does not bind to serum protein; 
however, most of the filtered carnitine is reabsorbed in proximal tubules. In accordance with this, jvs 
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mice exhibit increased carnitine urinary excretion, suggesting that OCTN2 is involved in renal 
reabsorption of carnitine [18,19,21].  OCTN2 protein has been immunolocalized at the apical 
membrane of the proximal tubular epithelial cells [22].  In addition, transport studies using 
membrane vesicles prepared from OCTN2-transfected cultured cells exhibit sodium ion dependence 
with an overshoot uptake in the presence of an inward-directed sodium ion gradient, in a membrane 
potential-dependent manner [22].  Since carnitine is co-transported with a sodium ion in each 
transport cycle via OCTN2/Octn2, this transport is electrogenic. Similar characteristics of carnitine 
transport have been observed in brush-border membrane vesicles isolated from kidney cortex [23].  
Sodium ion-dependent electrogenic transport is consistent with reabsorptive transport at the renal 
tubules.   In kidney epithelial cells in primary culture, sodium dependence of carnitine uptake from 
the luminal side across the apical membrane has been reported in rats and humans [24,25].  Apical 
membrane localization of OCTN2 protein might be controlled by interaction with PDZ protein, 
PDZK1 [26], because OCTN2 and PDZK1 proteins are co-localized in brush-border membrane of 
kidney tubular cells and coexpression of OCTN2 with PDZK1 results in an apparent increase in 
transport activity of OCTN2, but with unchanged affinity and membrane surface expression.  The 
precise mechanism of the increased activity of OCTN2 has not been established, but protein-protein 
interaction should be considered as an important determinant of efficient physiological reabsorption 
of carnitine mediated by OCTN2.  In summary, available evidence indicates that OCTN2 serves as 
a transporter for reabsorption of carnitine at the apical membrane of renal tubular epithelial cells. 
3-2: Intestine; The nature of the intestinal absorption mechanism of carnitine is controversial.  
Some studies show saturable and sodium ion-dependent apical uptake of carnitine [27,28], while 
others suggest no contribution of transporters [29].  However, a recent study in Caco-2 cells 
showed sodium ion-dependent carnitine uptake with similar characteristics to those of OCTN2 [30].  
The mRNA expression of OCTN2 is significant in human intestinal tissues along duodenum through 
colon, and the expression level is similar to that of another important nutrient transporter, PEPT1 [31, 
32].  Accordingly, OCTN2 is likely expressed in intestinal tissues and contributes to absorption of 
carnitine.  In addition, jvs mice exhibit a lowered absorption of carnitine after oral administration, 
resulting in reduced carnitine AUC in plasma (Table 2) [17].  In vitro transport studies in isolated 
intestinal tissues and enterocytes from jvs mice showed reduced uptake of carnitine compared with 
normal mice [33], whereas uptake of carnitine by enterocytes from normal mice was sodium 
ion-dependent and saturable with a Km of 12 M, which is similar to the Km of mouse 
Octn2-mediated carnitine transport, 22 M [4] (Table 1).  In addition, mouse Octn2 protein is 
localized at the apical membrane of the intestine in mice [34].  As in kidney, the apical membrane 
localization may be regulated by PDZK1, since Octn2 expression at the apical membrane is 
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decreased in Pdzk1-knockout mice [34].  Based on these results, OCTN2 and Octn2 are considered 
to contribute to intestinal absorption of dietary carnitine. 
3-3: Skeletal muscle and heart; Carnitine is stored in muscle tissues, so that its intramuscular 
concentration is maintained at high levels [35].  In heart, OCTN2 protein is present in vascular 
endothelium [36].  As shown in Table 2, in jvs mice the carnitine distribution into muscular tissues, 
in particular heart and skeletal muscle, is significantly reduced [18].  Systemic carnitine deficiency 
causes cardiomyopathy and skeletal muscle weakness, and carnitine uptake in cultured muscle cells 
involves a saturable process with Km lower than 10 M, which can be ascribed to a high-affinity 
transporter [37-39].  These observations suggest that OCTN2 is important for carnitine uptake in 
these tissues and a functional defect has a critical effect on normal tissue function.  The expression 
of OCTN2 protein in vascular endothelium in heart is likely to play a role in accumulation of plasma 
carnitine into heart tissues [36].  
3-4: Liver; One of the symptoms of SCD is fatty liver, suggesting that carnitine is essential for 
normal liver function.  In jvs mice, hepatic uptake of carnitine is lowered, showing a significant 
increase in Km to 475 M as estimated from the saturation kinetics [40].  Normal mouse liver 
exhibits biphasic uptake kinetics with Km values of 4.6 M and 404 M for the high- and 
low-affinity components, respectively.  Accordingly, jvs mouse lacks the high-affinity transporter 
for carnitine, suggesting that Octn2 is responsible for high-affinity carnitine uptake in liver.  
Biosynthesis of carnitine occurs in liver, kidney and brain, since expression of the enzyme 
gamma-butyrobetaine dioxygenase, which produces carnitine from gamma-butyrobetaine, is limited 
to these tissues.  Since gamma-butyrobetaine is produced in many tissues and released into the 
blood circulation, these three tissues may utilize gamma-butyrobetaine as a precursor of carnitine 
biosynthesis [41].  Our laboratory has shown that OCTN2 transports gamma-butyrobetaine as a 
substrate in a sodium ion-dependent manner with Km 12.9 M [42].  Hence, OCTN2 may be 
involved in controlling the intracellular pool of this precursor.  However, uptake of 
gamma-butyrobetaine is not exclusively due to OCTN2 in liver; the contribution of OCTN2 has been 
estimated to be approximately 30%.  We have found that gamma-butyric acid transporter subtype 
GAT2 is involved in supply of gamma-butyrobetaine to the liver [42,43].  In jvs mice, 
administration of gamma-butyrobetaine, but not carnitine, increased carnitine concentration in brain, 
liver, and kidney [44].  However, in normal mice, such an increase of carnitine concentration in 
these tissues was not observed after administration of gamma-butyrobetaine.  In addition, the 
hepatic concentration of free fatty acids was decreased after gamma-butyrobetaine treatment only in 
jvs mice, but not in normal mice.  These results together suggest that GAT2 is an alternative 
transporter responsible for taking up gamma-butyrobetaine into the liver for biosynthesis of carnitine 
in hepatocytes to supply other tissues, when OCTN2 is not functional due to genetic mutation, as 
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observed in SCD.  Usually, carnitine is administered to patients who show low systemic carnitine 
concentrations.  However, for those who suffer from SCD, it might be better to supply 
gamma-butyrobetaine but not carnitine itself, since these patients have significantly reduced 
carnitine transport activity, but retain GAT2 activity.   
3-5: Blood-brain barrier; Supplementation of carnitine and/or acetylcarnitine may have benefit in 
the central nervous system (CNS) to improve diseases such as Alzheimer’s disease, depression, and 
chronic fatigue syndrome, presumably by supplying acetyl moieties, because it enhances 
mitochondrial function and antioxidant effect in the CNS [45-47]. Accordingly, 
carnitine/acetylcarnitine needs to be translocated into brain across the blood-brain barrier.  OCTN2 
is indeed expressed in brain [3] and the presence of OCTN2 in brain capillary endothelial cells that 
constitute the blood-brain barrier has been demonstrated [48-51].  Studies using our in vivo and in 
vitro cultured cell models for blood-brain barrier transport have indicated that acetylcarnitine is 
significantly taken up by brain from the blood side, and the endothelial cellular uptake of 
acetylcarnitine has similar characteristics to those of OCTN2 [48].  An in situ brain microdialysis 
study suggested the movement of acetylcarnitine from blood to CNS [49].  OCTN2 and other 
amino acid transporters are likely involved in blood-brain barrier transport of carnitine [50], while 
OCTN2 might exists on the brain side but not the blood side, and so may contribute to transport of 
carnitine/acetylcarnitine from brain to blood [51].  Although the precise contribution of OCTN2 at 
the blood-brain barrier remains unclear, it should contribute to CNS function by regulating 
concentrations of carnitine and acetyl moiety in the brain. 
3-6: Mammary glands and placenta; Carnitine and acylcarnitine are present at higher 
concentrations in the fetal circulation than in the maternal circulation, and the fetus has limited 
ability to synthesize carnitine.  Therefore, it is possible that maternal carnitine is supplied to the 
fetus across the placental barrier [52].  In placenta-derived choriocarcinoma cells, sodium 
ion-dependent transport of carnitine with Km 12 M has been reported [53].  The transport system 
has affinity for both L- and D-carnitine, acetylcarnitine and other compounds, but has no affinity for 
choline.  These characteristics are similar to those of OCTN2.  Gene expression and protein 
localization of OCTN2 protein at the apical membrane of syncytiotrophoblast have been observed 
[54].  Furthermore, apical membrane vesicles, but not basolateral membrane vesicles, prepared 
from syncytiotrophoblast are able to mediate sodium-dependent uptake of carnitine with Km 21 M.  
In jvs mice, carnitine accumulation in fetal tissues is significantly lower than in normal mice; 
however, significant up-regulation of fatty acid oxidation-related enzymes is also observed in 
placental tissues of jvs mice [55].  This observation suggests that OCTN2 is essential to maintain 
energy supply in placenta and fetus, and the reduced carnitine level may be compensated by 
increased enzyme activity of fatty acid oxidation.  Neonates also need carnitine to generate energy 
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via beta-oxidation of long-chain fatty acids, in particular to maintain brain function, since they are 
not able to synthesize enough carnitine. Accordingly, carnitine should be supplied to neonates in 
milk.  Indeed, the concentration of carnitine in milk (0.32 mM) after 24 h nursing was 
approximately 10 times that in plasma in rats [56]. Interestingly, the carnitine concentration declines 
gradually during lactation, which may suggest that the neonate acquires increased activity to 
synthesize carnitine.  There is a report that carnitine transport in mammary gland exhibits sodium 
ion dependence in rats [57].  Carnitine transport was inhibited by D-carnitine and acetylcarnitine 
but not by choline, showing similar characteristics to those of OCTN2, though the obtained Km was 
relatively high (132 M). In MCF12A cells derived from human mammary gland epithelial cells, 
high- and low-affinity transport processes for carnitine with Km values of 5.1 M and 15.9 mM, 
respectively, are present; it seems likely that the high-affinity component is mediated by OCTN2 
[58].  OCTN2 protein is detected in the alveolar epithelia of mammary gland, apparently at a 
sufficient level to supply carnitine to milk.  In mice, Octn1, 2, and 3 are all expressed in mammary 
gland [59].  Their intracellular localization in mammary gland is not known; however, Octn1 is 
expressed mainly in blood vessel endothelium and secretory alveolar apical membrane, Octn2 in 
secretory alveoli, and Octn3 in interstitial space and blood vessel endothelium.  Their expression 
level in epithelial ducts is increased in pregnant and lactating mice, compared to virginal mice, and 
then the levels decrease after cessation of lactation, so that the expression profile of OCTN 
transporters is similar to the change of carnitine concentration in milk.  Accordingly, carnitine 
transporters including OCTNs are thought to transfer carnitine to milk from maternal blood.                    
4: Roles of OCTNs in male reproductive tissues and germ cells  
In male reproductive tissues, carnitine and acetylcarnitine concentrations are higher than in plasma 
and carnitine is likely an important nutrient for maturation and motility of spermatozoa [60].  
OCTNs are present in testis and have been suggested to contribute to carnitine/acetylcarnitine 
handling [2,3]. The structure of male reproductive tissues and localization of expression of 
OCTNs/Octns are illustrated in Figure 2. Spermatozoa are produced in testis and move to epididymis. 
They mature to fertile sperms during the transition to epididymis.  Spermatozoa are immotile in the 
proximal part of epididymis, where carnitine concentration in epididymal plasma is low.  However, 
with increase of carnitine/acetylcarnitine concentration along the epididymis from caput to corpus 
and cauda, the number of motile spermatozoa increases [60].   
Mouse Octn3 is selectively expressed in the testis [4], and human CT2 (SLC22A16), which is not 
classified into the OCTN family but has about 33% similarity to mouse Octn3, and shows similar 
functional characteristics of sodium ion independence and high affinity for carnitine, is also 
expressed in testis [61]. In Sertoli cells, which form a part of the blood-testis barrier, carnitine 
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transport is sodium ion-dependent and exhibits biphasic kinetics, suggesting contributions of 
OCTN2 and ATB0,+ , which was firstly found as amino acid transporter, to high- and low-affinity 
transport, respectively [62-64].   
Uptake of carnitine by primary-cultured rat epididymal cells in suspension shows high- and 
low-affinity transport components, and the sodium ion dependence and inhibitor susceptibility of the 
high-affinity transport are similar to those of OCTN2 [65].  Octn2 protein is localized to the 
basolateral side of epithelial cells, with higher expression at the distal caput, corpus and proximal 
cauda in rats [66].  Although rat Octn1 expression in epididymal tissues is low, it is detectable in 
testis and epididymal tissues from caput to cauda [66].  Human CT2 is a sodium ion-independent 
transporter, like mouse Octn3, and is expressed at the luminal membrane of epididymal epithelial 
cells [61]. Accordingly, Octn3/CT2 should play a role in transport of carnitine in this tissue.  
However, in a carnitine transport experiment with suspended epididymal epithelial cells, sodium 
ion-dependent transport was observed, showing a discrepancy between the expression of transporters 
(Octn3/CT2) and the observed activity (sodium-dependent carnitine uptake) [65].  In experiments 
using suspended epididymal tissue, it is easier to detect basolateral transport than luminal transport 
[65].  Accordingly, it is possible that only sodium ion-dependent uptake of carnitine, which 
corresponds to basolateral uptake, might have been detected using this experimental method, and 
that sodium ion-independent transport of carnitine is actually present at the luminal side of 
epididymal tissues, but was not detected with this method.  Carnitine is highly accumulated in 
epididymal plasma.  This may be explained by the following mechanisms: OCTN2-mediated 
sodium ion-dependent active transport imports carnitine from the blood into epithelial cells, from 
which it is released to the lumen via sodium ion-independent CT2 transporter. However, in mice 
Octn2 is localized to the luminal membrane of epididymal epithelial cells, particularly the distal 
corpus and cauda [67, 68]. There may be several reasons for this, including the presence of splice 
variants and species difference.  Although further studies are required, it is clear that OCTN2 is 
essential to maintain a high concentration of carnitine in the distal part of epididymal luminal plasma, 
based on the above findings and the observation of male infertility in jvs mice due to obstructive 
azoospermia [69].   
Expression of OCTNs in spermatozoa is interesting, since their expression shows site selectivity [70]. 
In mice, epididymal spermatozoa show partial sodium ion-dependent transport with Km values of 
23.6 M and 6.57 M for carnitine and acetylcarnitine, respectively. The uptake activity is higher in 
spermatozoa obtained from corpus than in those from caput or cauda, both in the presence and 
absence of sodium ions. Accordingly, a contribution of sodium ion-dependent or -independent 
transporters is possible.  Immunocytochemical studies of the expression of mouse Octn1, 2 and 3 
proteins in spermatozoa from caput, corpus and cauda showed selective expression of Octn2 and 3 in 
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the tail of spermatozoa, though expression of Octn1 protein is low (Figure 3). Octn3 expression is 
higher in the spermatozoa obtained from corpus and cauda than caput.  Furthermore, although 
Octn2 and 3 are present in spermatozoa, their localizations are distinct, since they are expressed in 
the principal piece of the tail and middle piece of the tail, respectively (Figure 3).  Several reports 
have suggested passive uptake of carnitine/and acetylcarnitine by these sperm cells. However, the 
selective expression of OCTN proteins and the uptake characteristics observed in spermatozoa 
indicate that OCTN transporters are responsible for the uptake of carnitine and acetylcarnitine to 
fertile spermatozoa.  Expression profiles of Octns in male reproductive tissues and germ cells are 
illustrated in Figure 2.  
 
5: OCTNs and autoimmune diseases. 
Because of the physiologically essential role of carnitine in beta-oxidation of long-chain fatty acids 
to produce ATP, functional defect of OCTN2 leads to failure to maintain an appropriate systemic 
concentration of carnitine by reabsorption of filtered carnitine and thus to an inadequate supply of 
carnitine to various tissues as described above, directly resulting in carnitine deficiency-related 
diseases such as skeletal muscle weakness, cardiomyopathy, male infertility, and others.  The 
symptoms observed in jvs mice clearly demonstrate the importance of OCTN2-mediated carnitine 
transport in the corresponding tissues [71]. In addition to these symptoms due to carnitine deficiency, 
current evidence suggests an association of OCTNs with various diseases, including rheumatoid 
arthritis, Crohn’s disease and asthma, though the mechanisms involved remain enigmatic.  It has 
been reported that SNP in intron 1 of the OCTN1 gene affects the expression of OCTN1 by lowering 
affinity for the transcription factor RUNX1 [9,10]. In addition, the RUNX1 gene is independently 
associated with autoimmune diseases such as rheumatoid arthritis [9].  Similarly, SNPs in OCTN1 
and OCTN2 genes are associated with susceptibility to Crohn’s disease [10]. In Octn1-knockout 
mice, the absorption and disposition of its substrate ergothioneine are changed and these mice 
exhibit a higher susceptibility to intestinal inflammation [11].  Since OCTN1 protein is expressed 
in intestinal epithelial cells and its functional defect significantly affects the intestinal disposition of 
ergothioneine, OCTN1 might be related to many intestinal diseases, though the mechanisms remain 
to be clarified [72].  More recently, pharmacogenomic attempts to understand the relevance of 
OCTN1 and OCTN2 to susceptibility to Crohn’s disease have uncovered a significant association in 
Caucasians, but not in an East Asian population [73].  Asthma is a disease that may involve 
heritability and alteration in several associated genes.  SLC22A5 may be one of them, based on SNP 
analysis in asthmatics and unaffected persons [74].  Expression of OCTN1 and OCTN2 in airway 
epithelial cells has been reported to be localized at the luminal membrane of epithelial cells and the 
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transporters are functional, since the substrates ergothioneine, carnitine and the anti-cholinergic drug 
ipratropium are taken up by cells with similar characteristics to those observed in vitro for 
OCTN1/2-expressing cells [75,76]. Although little is yet known about the mechanism, it is possible 
that OCTN1/2 expressed in respiratory tissues is involved in the normal physiological function of 
airways and its disruption may lead to asthma. 
6: Drug transport and pharmacological and toxicological relevance of OCTNs 
6-1: Substrate selectivity of OCTNs and their difference; OCTN1 and OCTN2 preferentially 
transport ergothioneine and carnitine/acetylcarnitine, respectively.  They also accept various 
xenobiotics/drugs as substrates (Table 1).  OCTN1 was first found as a transporter resembling the  
OCT family (SLC22A1, 2, and 3), and it mediated transport of TEA [2].  OCTN2 was the second 
member to be identified of the organic cation transporters that recognize TEA as a substrate, and the 
OCTNs were initially classified as polyspecific cation transporters, based on substrate specificity 
and inhibition profile [77].  However, we have shown that OCTN2 is a physiologically important 
carnitine transporter [3], while OCTN1 is an ergothioneine transporter [6,7].  Further, mouse Octn3 
displays negligible transport of the organic cation TEA, and preferentially transports carnitine [4].  
Similarly, CT2 is selective for carnitine and acylcarnitine and does not transport organic cations, 
thus showing similar specificity for carnitine-related compounds to mouse Octn3 [61].  Mouse 
Octn3 is a sodium ion-independent transporter for carnitine, and is distinct from OCTN2.  
Structural analysis of human OCTN2 and mouse Octn3 suggests that the sodium ion dependence of 
carnitine transport is associated with a few key amino acid residues, e.g. glutamine at codon 180 and 
glutamine at codon 207 of OCTN2, that are common to human, rat and mouse OCTN2s, but not to 
mouse Octn3, in which both of these residues are histidine [78].  This may be related to the fact that 
OCTN1 and OCTN2, but not Octn3, contribute to xenobiotic/drug transport.  Experimentally, 
quinidine, pyrilamine, verapamil, oxaliplatin, gabapentin, and ipratropium are known to be 
substrates of OCTN1 [2,12,13,14, 76].  Substrate drugs of OCTN2 include oxaliplatin, verapamil, 
spironolactone, mildronate, pyrilamine, TEA, quinidine, cephaloridine, imatinib and valproate 
[13,36,76,79,80,81,82] (Table 1).  There are also many inhibitors of OCTN1 and OCTN2 and those 
inhibitors may also be substrates of OCTNs, though there is no direct evidence for this.  However, 
there are some conflicting results with regard to substrates [83].  Further studies, such as molecular 
modeling of binding of substrates and inhibitors, in addition to precise functional studies are needed 
[84].  
6-2: Characteristics of substrate recognition of OCTN2; There are some interesting reports on the 
multiplicity of substrate recognition of OCTN2; for example, transport of carnitine is sodium 
ion-dependent, but transport of cationic xenobiotics is sodium ion-independent [79,85].  
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Physiologically, the electrochemical potential of sodium ion is inwardly directed and it is clear that 
carnitine is taken up by cells via OCTN2, but not transported out of cells via OCTN2.  Interestingly, 
in jvs mice, which lack functional Octn2, the changes in tissue distribution and urinary excretion of 
the organic cation TEA from normal mice were distinct in part from those observed for carnitine 
(Table 2) [86]. Although the tissue distribution of TEA in most tissues was decreased in jvs mice 
similarly to that of carnitine, it was significantly increased in kidney (Kp values in kidney: for TEA, 
9.89 in wild-type and 25.0 in jvs mice; for carnitine, 31.6 in wild-type and 10.8 in jvs mice).  In 
contrast, urinary secretory clearance of TEA was decreased in jvs mice from 6.25 to 3.43 mL/min/kg, 
while total clearance of carnitine was increased in jvs mice from 2.45 to 6.7 mL/min/kg (Table 2).  
Accordingly, renal handling of TEA in jvs mice is quite different from that of carnitine. Considering 
the renal handling of TEA and carnitine, which are actively secreted and reabsorbed, respectively, 
such an observed change in TEA disposition implies that renal secretion of TEA is decreased in jvs 
mice, while reabsorption of carnitine is decreased in jvs mice.  Thus, OCTN2 appears to contribute 
bidirectionally to secretion of cationic compounds, as well as contributing to reabsorption of 
carnitine. This apparent discrepancy may be due to the difference in sodium ion dependence of 
OCTN2-mediated transport between TEA and carnitine.  Since TEA transport mediated by OCTN2 
shows pH dependence but not sodium ion dependence and OCTN2 is expressed at the apical 
membrane of tubular epithelial cells [77], OCTN2-mediated TEA transport is partly driven by an 
inwardly directed proton gradient and TEA is exchanged with protons via OCTN2.  This 
mechanism is distinct from sodium ion-dependent carnitine transport via OCTN2. The hypothetical 
mechanisms of OCTN2-mediated sodium ion-dependent carnitine and pH-dependent TEA transport 
are shown in Figure 4.  Sodium ion requirement for carnitine transport may be mechanistically 
explained by the presence of the carboxyl moiety in carnitine, but not TEA, and the sodium 
ion-binding site on OCTN2 is close to the site that recognizes the carboxyl moiety of carnitine, while 
this site is not directly involved in binding of TEA on OCTN2 [85].  This model is shown in Figure 
5.   The idea that the binding sites of carnitine and cationic compounds are not identical, but are 
partly shared, can explain the difference in the apparent effects of mutations of OCTN2 protein on 
the transport activity towards these two types of compounds [85].  
 
6-3. OCTN-mediated absorption of inhaled drugs; Although it has not yet been proven, OCTNs 
might be involved in transport of inhaled drugs, influencing the efficacy and toxicity of these drugs.   
OCTNs are expressed in lung [2,3] and the anti-cholinergic ipratropium bromide (ipratropium) has 
been shown to be a substrate of OCTN2 using Caki-1 cells, which are derived from human kidney 
proximal cells expressing OCTN2 at the apical membrane [87]. The uptake of ipratropium by an 
artificial expression system of OCTN1 and OCTN2 was significantly higher than of non-transfected 
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cells and Km values for its transport were 444M and 53 M, respectively [76], although 
ipratropium is also transported by OCT1 and OCT2 [88].  Ipratropium is a quaternary cationic drug 
and is effective after inhalation for chronic obstructive pulmonary disease and asthma, so it must 
cross airway epithelial cells to exert its pharmacological activity.  Since ipratropium is hydrophilic 
and is a substrate of OCTN2, its transport by OCTNs in human bronchial epithelial cell line 
BEAS-2B has been studied [76]. Ipratropium uptake by BEAS-2B cells via OCTNs was 
characterized by silencing OCTN2 mRNA expression; this resulted in a significant decrease of 
uptake, suggesting that OCTN2 expressed in the airway epithelial cells is involved in the absorption 
of ipratropium, and presumably also tiotropium bromide, after inhalation.  A carnitine ester prodrug 
of prednisolone has been synthesized to target bronchial epithelial cells after delivery by inhalation, 
in the expectation of OCTN-mediated bronchial epithelial absorption [89].  Such prodrugs are 
likely transported by OCTN2 in BEAS-2B cells.  OCTN2, and to a lesser extent OCTN1, may 
contribute to airway absorption of such inhaled drugs, for selective delivery to their pharmacological 
target(s).  To date, pulmonary drug delivery has not been well characterized, but OCTNs and other 
transporters, including OCTs, may contribute to drug absorption from lung [90].  It is reported that 
the air-interfaced cultured cell line Calu-3 expresses OCTNs as well as OCTs [91], and is a suitable 
model to evaluate transport of inhaled drugs [92].   
6-4. OCTN and platinum anticancer drug toxicity; Cisplatin and some other platinum anticancer 
drugs cause toxicity in kidney, and organic cation transporters are likely involved in this 
drug-dependent toxicity by causing them to accumulate in kidney tubular epithelial cells [93,94].  
For example, the dose-limiting toxicity of oxaliplatin is neuropathy due to drug accumulation in 
dorsal root ganglion [95], and OCTNs might be involved in this accumulation [14].  Oxaliplatin is a 
substrate of OCTN1 and OCTN2, and HEK293 cells transfected with OCTN1 and OCTN2 exhibited 
higher sensitivity to oxaliplatin-induced toxicity.  Further, OCTN1 and OCTN2 are both expressed 
in cultured dorsal root ganglion cells from rats.  Hence, intracellular accumulation of oxaliplatin in 
dorsal root ganglion cells could be due to uptake by the OCTNs.  In this regard, reducing the 
accumulation of oxaliplatin by administration of OCTN inhibitors may be useful to prevent 
oxaliplatin-induced neurotoxicity [14].         
6-5. Drug-induced secondary carnitine deficiency; Drug-induced carnitine deficiency is 
sometimes caused by clinically administered drugs such as cefditren pivoxyl and valproic acid 
[96,97].  It has been considered that OCTN2-mediated reabsorption of carnitine might be inhibited 
by these drugs, resulting in a decrease of plasma concentration of carnitine.  Although valproic acid, 
emetin and pivalic acid are known to cause secondary carnitine deficiency or to have an inhibitory 
effect on OCTN2-mediated carnitine transport, their inhibitory potencies may not be sufficient to 
account for the clinical observations [79].  An alternative possibility is that carnitine esters formed 
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with pivalic acid and valproic acid may not be reabsorbed well, resulting in decreased reabsorption 
of carnitine [98,99,100].  In addition, carnitine esters have the potential to inhibit OCTN2-mediated 
reabsorption of carnitine to some extent, so these drugs may cause drug-induced secondary carnitine 
deficiency.           
7: Conclusion 
The key physiological role of OCTNs appears to be transport of carnitine, which is required for 
energy supply through beta-oxidation of long-chain fatty acids.  Any disturbance of carnitine 
homeostasis is likely to affect heart and skeletal muscle function, as well as male fertility.  
Furthermore, genetic variations of OCTN genes are associated with severe diseases, including 
autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and asthma.  Accordingly, 
studies of carnitine-related systems may provide clues to the mechanisms of these diseases.  In 
addition, clinically used drugs that disturb carnitine homeostasis might lead to adverse effects, such 
as heart failure and myopathy. Therefore, a detailed understanding of OCTNs is expected to be 
clinically important in various respects.  In addition, OCTNs contribute to the absorption and 
disposition of various therapeutic drugs, and may influence their pharmacokinetics and 
pharmacological activity. Accordingly, a better understanding of the interaction of drugs with 
OCTNs should be clinically beneficial, and in addition, there is the possibility of targeting OCTN 
transporters to modulate drug activity or side effects. 
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Comparison of pharmacokinetic parameters of carnitine and TEA in normal and jvs mice 
 
Parameters Carnitine TEA 
 wild jvs wild jvs 
AUC1-4hr (ng min/mL) iv 29.2 39.8 - - 
                  po 19.7 13.6 - - 
Bioavailability (%) 67.5 34.1*   
     
Vdss (L/kg) 8.16 1.10* 1.3 1.63 
     
CLtotal (mL/min/kg) 2.45 6.7** - - 
CLsecretion (mL/min/kg) - - 6.25 3.43* 
     
Tissue to plasma ratio (Kp)      
Brain 1.14 0.8 0.081 0.039* 
Lung 20.7 9.5* 5.29 3.7* 
Heart 24.4 1.22* 0.961 1.35 
Liver 29.5 8.34* 16.7 4.55* 
Kidney 31.6 10.8* 9.89 25.0** 
Gut 15.8 5.37* 6.32 5.7 
Spleen 31.6 5.07* 5.90 2.47* 
Muscle 2.16 0.54* 0.843 0.783 
 indicates a significant decrease (P<0.05) and ** indicates a significant increase (P<0.05).  







Figure 1: Schematic illustration of the involvement of OCTNs in carnitine disposition and role of 
carnitine in -oxidation of long chain fatty acids in various tissues. 
Carnitine is supplied mainly from food and partially via biosynthesis.  In kidney, carnitine is 
filtered and efficiently reabsorbed by OCTN2.  Carnitine in plasma is taken up by OCTN2 and 
other transporters into tissues, where -oxidation of fatty acids occurs. Then acylcarnitine is formed 
in the cells via CPT1 and crosses the mitochondrial inner membrane via carnitine acylcarnitine 
translocase CACT for -oxidation.  Carnitine is essential in this reaction. ATP production is 
lowered by carnitine deficiency, resulting in a range of symptoms, including cardiomyopathy, 
skeletal muscle weakness, fatty liver and male infertility.    
 
Figure 2: Differential expression of Octns in male reproductive tissues of mouse. 
Spermatozoa in seminiferous tubule, initially formed from germ cells in testis, move out of the testis 
via efferent ductules to epididymis.  The epididymis is divided into three parts, the caput (upper 
part), corpus (middle part) and cauda (lower part) and the spermatozoon gains motility during 
passage from caput to cauda. The carnitine concentration in the luminal fluid in epididymis 
gradually increases from the upper to lower part.  Octns are expressed as indicated and are 
considered to control carnitine concentration in seminiferous fluid in the epididymal lumen and in 
epithelial and Sertoli cells.  
 
Figure 3: Differential expression of Octns in mouse spermatozoa. 
Mouse spermatozoa obtained from caput, corpus and cauda were stained with antibodies to Octn1, 
Octn2, and Octn3.  Each Octn protein was visualized using Alexa Fluoro594 goat anti-rabbit Ig-G 
conjugate after reaction with the corresponding anti-Octn antibodies (Red).  Nuclei were stained 
with DAPI (blue).  The staining of octn1 is low, but staining of Octn2 and Octn3 is high in corpus 
and cauda, compared with caput.  Cellular localizations of Octn2 and Octn3 are in the tail and a 
distinct part of spermatozoa.  Octn2 and Octn3 are stained in the principal piece and middle piece 
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of the tail, respectively. This difference in expression profiles may be related to the maturation of 
spermatozoa. For details, see reference 70. 
 
Figure 4: Model of OCTN2-mediated transport of carnitine and organic cation TEA in renal tubular 
epithelial cells. 
Carnitine in tubular lumen is taken up by cells in a sodium ion-dependent manner, while TEA 
transport is sodium ion-independent.  The carnitine binding site is only functional when sodium ion 
is present on the same side.  Accordingly, carnitine transport via OCTN2 is in the direction of 
reabsorption, whereas organic cations accumulated in cells via basolateral OCT2 are removed partly 
by OCTN2 in a partially pH-dependent manner.  Accordingly, OCTN2 might act as a reabsorptive 
transporter for carnitine and a secretory transporter for organic cations via different mechanisms. 
The hypothetical model is described in more detail in reference 86.    
 
Figure 5: Model of substrate binding sites of OCTN2. OCTN2 accepts zwitter-ionic carnitine, 
quaternary cation TEA, and acidic valproic acid.  Furthermore, transport of carnitine is sodium 
ion-dependent, while that of TEA is sodium ion-independent.  Valproic acid displays sodium 
ion-dependent affinity for OCTN2 [reference 85].  Accordingly, it is presumed that there are at 
three determinant sites on OCTN2 that independently accept positively and negatively charged 
substrates and sodium ion.  The sodium ion-binding site is very close to the site that recognizes the 
negative charge of a substrate, since TEA (cationic charge only) does not show sodium 
ion-dependent transport.  Because of the presence of substrate-dependent binding sites on OCTN2 
protein, mutations of certain amino acid residues of OCTN2 have differential effects on transport of 
TEA and carnitine [reference 85].   
    
OCTN2OCTN2
Biosynthesis (Lys, Met)





















































































































Cation Site Anion Site
CH   COO
CH3-CH2-CH2
CH3-CH2-CH2
Valproate
Na+ Site
